Fig. 6

Kaplan–Meier curves for comparison of overall survival in advanced gastric cancer patients who received nivolumab among four groups: patients without cancer cachexia for the overall period (Group A), patients who newly developed cancer cachexia during treatment (Group B), patients who had an improvement in cancer cachexia after the start of treatment (Group C), and patients who had cancer cachexia throughout the overall period (Group D). Data were statistically compared by the log-rank test